Quite a few statin posts in the past few months... not sure if this was among them, but is very recent. [Edited below] Hat tip to Richard Wassersug at LifeonADT.com for posting.
pubmed.ncbi.nlm.nih.gov/350...
Abstract
Background: Metabolic syndrome and its pharmacologic treatment can potentially influence the progression of prostate cancer in men receiving (ADT). We aimed to evaluate the association between metabolic syndrome and its pharmacologic treatment with time to castration-resistant prostate cancer (CRPC).
Methods: We identified 409 men with metastatic castration-sensitive prostate cancer receiving first line ADT from 1996 to 2014 at our institution. Researchers collated data on metabolic syndrome, statin use, aspirin use, and metformin use. Flexible parametric survival models were used to calculate hazard ratios of the association between metabolic conditions and time from ADT initiation to CRPC.
Results: During a median follow-up of 59 months, 87% men progressed to CRPC. Median time to CRPC was 19 months. Fifty-six percent of men met the definition of metabolic syndrome. Metabolic syndrome was associated with shorter time to CRPC . Importantly, in men with metabolic syndrome, statin use was associated with a slower progression to CRPC.
Conclusions: Our study suggests that metabolic syndrome is a risk factor for earlier progression from castration-sensitive to castration-resistant prostate cancer and raises the possibility that treatment, such as statin use, may slow the time to progression.